Rezultati pretraživanja
  1. prije 7 sati

    announced today the completion of its previously announced underwritten public offering of 1,905,000 shares of its common stock at a price to the public of $21.00 per share. gross proceeds to Albireo of approximately $46.0 million and net proceeds of approximately $42.9M

  2. prije 9 sati

    Albireo Announces Closing of $46 Million Public Offering Including Exercise in Full of Underwriters’ Option t

  3. 3. velj

    -$1.56 Earnings Per Share Expected for Albireo Pharma Inc This Quarter

  4. 2. velj

    Albireo Pharma Inc Receives Consensus Recommendation of “Buy” from Analysts

  5. 1. velj
    Odgovor korisnicima

    Further will be on market in PFIC by early 2021... and alagile and biliary trials start soon. not sure why you think 4/5 years, that is a misrepresentation from my read of things. I think PFIC on market in 2021, and the others 2022...

    1 reply 1 proslijeđeni tweet 2 korisnika označavaju da im se sviđa
  6. 1. velj
    Odgovor korisniku/ci

    The cumulative royalty burden could add up to about 15%. I like and they could have a better IBAT drug but I would be careful. Data is presented differently and I disagree on AE rate. Bottom line, has BTD and has nod to file for ALGS soon, may be 4-5 yrs away.

    1 reply 1 proslijeđeni tweet
  7. 1. velj
    Odgovor korisniku/ci

    The drug has huge royalty burden and failed multiple trials and has high AE rate. This is a venture capital money grab exploiting a loop hole. If you are interested in IBAT as an MOA - check out . The S1 for mirum is gnarly. Shire gave up on the mirum drug.

    1 reply 1 proslijeđeni tweet 2 korisnika označavaju da im se sviđa
  8. 31. sij

    Late night studying missed opportunities, from stocks I had on watch. Screen time, screen time. Today’s late night charts , , , , and which gave 11:1 R:R crazy haha, my aim is 2:1 doubt I would’ve been that patient with it.

    1 reply 1 proslijeđeni tweet 6 korisnika označava da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
  9. 31. sij

    Small-cap stocks gapping down in trading Thu Jan 30th - - More: -

    1 proslijeđeni tweet
  10. 30. sij

    asset watch- stocks with volume spikes on Thursday -

    Estate Planning, Estate Asset Attorney
    The Burdette Law Firm
  11. 30. sij

    In Play: , , , , , , , High Uncertainty: , ,

  12. 30. sij

    Watchlist , , , , , and .

    1 korisnik označava da mu se sviđa
  13. 30. sij

    Albireo Prices $40 Million Public Offering of Common Stock

    1 proslijeđeni tweet
  14. 30. sij

    tonight's offering might provide an entry point if interested in this name "The company is expected to offer the shares at $21 each, Bloomberg reports - an 11.9% discount to the closing price."

    5 korisnika označava da im se sviđa
  15. 29. sij

    Albireo Achieves Significant Milestones for Odevixibat Across Multiple Diseases

  16. 29. sij

    offering.

  17. 29. sij

    Albireo Pharma Inc Forecasted to Earn FY2024 Earnings of $16.52 Per Share

  18. 29. sij

    Wedbush Sets Albireo Pharma FY2024 Earnings Estimates at $16.52 EPS.

  19. 29. sij

    Wedbush Weighs in on Albireo Pharma Inc’s FY2024 Earnings

Nema rezultata.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.